Photo of Ashutosh Tewari

Ashutosh Tewari

  • PROFESSOR & CHAIR Urology
Print ProfilePrint Profile

Specialty

Certifications

  • American Board of Urology

Education

  • MBBS, G.S.V.M. Medical College

  • Residency, Surgery
    G.S.V.M. Medical College

  • Residency, Urology
    Henry Ford Hospital

  • Fellowship, Transplant
    University of Liverpool

  • Fellowship, Urology Oncology
    University of California - San Francisco

  • Fellowship, Urology Oncology
    University of Florida

  • Fellowship, Urology Oncology
    Henry Ford Hospital

Biography

    Ashutosh (Ash) K. Tewari, MD, Chairman, Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai is a world-renowned urologist and prostate cancer specialist. As Director of the Department of Urology, he leads a multidisciplinary team committed to improving prostate cancer treatment, research and education. To date, he has performed over 5,000 robotic radical prostatectomy surgeries. The Tewari Lab is working on unlocking the genomic causes of prostate cancer and translating genomic information to practical physician application through imaging. In 2012, he was awarded the American Urological Association’s Gold Cystoscope Award. This honor is given annually to the urologist who has contributed significantly to the field within 10 years of completing residency. Dr. Tewari holds several leadership positions domestically and internationally.

    Dr. Tewari received his undergraduate and medical degrees at GSVM Medical College (Kanpur, India). During medical school he was awarded 17 Gold Medals for outstanding performance on university exams. Dr. Tewari completed his first urology residency at Sanjay Gandhi Post Graduate Institute of Medical Sciences (Lucknow, India). He completed fellowships in urologic-oncology at University of California, San Francisco and the University of Florida (Gainesville, FL). In 2004, he completed his second urology residency at Henry Ford Hospital (Detroit, Michigan). While at Henry Ford, Dr. Tewari was part of the team that performed the first robotic radical prostatectomy in the United States.

    Clinical Care

    Dr. Tewari’s case series is one of the largest in the world and his outcomes are considered the gold standard for this procedure. Dr. Tewari’s clinical expertise in prostate cancer includes targeted biopsies, cystoscopies, robotic prostatectomies, as well as the management of active surveillance prostate cancer patients. He has also initiated clinical protocols investigating the utility of focal therapy platforms for the treatment of prostate cancer. Dr. Tewari has been consecutively listed in New York Magazine’s Top Doctors issue since 2006. Learn more at his Center for Prostate Cancer website.


    Research
    Dr. Tewari’s research approaches the problem of prostate cancer from distinct perspectives.

    His outcomes research group is investigating the epidemiological effects of prostate cancer. He is also investigating several novel imaging techniques for identifying prostate cancer imaging biomarkers. And Dr. Tewari is working to unlock the genomic causes of prostate cancer.

    As a researcher, Dr. Tewari has authored over 250 peer-reviewed articles, book chapters, and textbooks on prostate cancer and robotic surgery. This includes several high-impact articles in Nature, Cell, and PNAS. Most recently he has edited Prostate Cancer: A Comprehensive Perspective (Elsevier 2013).

    In addition to his publications, Dr. Tewari is the recipient of three major NIH Federal research awards. This includes an R01 grant, in which he serves as Principal Investigator, investigating the utility of multiphoton microscopy during prostate cancer treatment. Dr. Tewari also serves as site-PI for the NIH/NCI The Cancer Genome Atlas Tissue Source Site and the NIH/NCI Early Detection Research Network. In addition to his Federal funding, Dr. Tewari is currently funded by the Prostate Cancer Foundation, Boston Scientific, and Medtronic. He has initiated collaborative work with several other leading institutions including Cold Spring Harbor Laboratory, the Broad Institute of MIT and Harvard, The Koch Institute for Integrative Cancer Research at MIT, Dana-Farber Cancer Institute, and Rockefeller University,


    Training

    Dr. Tewari has trained over 30 fellows and residents in robotics. His fellows have gone on to establish successful prostate cancer programs in Canada, Great Britain, India, Japan and Singapore. Dr. Tewari hosts an annual international prostate cancer symposium. Each year nearly 1000 attendees attend this symposium to discuss the latest breakthroughs and emerging topics in prostate cancer treatment and research. The proceedings of this meeting are covered by European Urology (the urology journal with the highest impact factor).

     
    Current Affiliations

    Dr. Tewari is affiliated with over 40 professional associations and organizations, including:
    -Member, American Urological Association

    -Member, Society of Minimally Invasive Surgery

    -Member, Society of Robotic Surgery (SRS)

    -Member, Society of Urologic Oncology (SUO)

    -Fellow, New York Academy of Medicine

    -Associate Editor, AUA News

    -Associate Editor, BJUI

    -Reviewer, Journal of Urology

    -Reviewer, European Urology

Awards

  • 2012 -
    Gold Cytoscope Award
    AUA

  • 2012 -
    First Prize Best Abstract
    EAU

  • 2012 -
    Most Compassionate Doctor Award
    Vitals

  • 2011 -
    Yahya Cohen Memorial Lecture and Medal
    College of Surgeons of Singapore

  • 2011 -
    American Society of Clinical Oncology Merit Award
    ASCO GU

  • 2009 -
    Syme Medal
    Royal College of surgeons of Edinburgh

  • 2009 -
    BJU International Visiting Professor Award
    BJU

  • 2008 -
    Grand Prize
    International College of Surgeons Research Essay

  • 2007 - 2013
    America's Best Doctors
    Castle Connolly

Publications

.;.

Knelson EH, Gaviglio AL, Tewari AK, Armstrong MB, Mythreye K, Blobe GC. Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. The Journal of clinical investigation 2013 Oct;.

Nguyen DP, Li J, Yadav SS, Tewari AK. Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer. BJU international 2013 Oct;.

Ali A, Nguyen DP, Tewari A. Robot assisted laparoscopic prostatectomy in 2013. Minerva chirurgica 2013 Oct; 68(5).

Kluth LA, Xylinas E, Rieken M, Chun FK, Fajkovic H, Becker A, Karakiewicz PI, Passoni N, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Guillonneau B, Rouprêt M, Briganti A, Scherr DS, Graefen M, Tewari AK, Shariat SF. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. Urologic oncology 2013 Sep;.

.;.

Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin-6. BJU international 2013 Sep;.

.;.

Rieken M, Kluth LA, Xylinas E, Seitz C, Fajkovic H, Karakiewicz PI, Lotan Y, Briganti A, Loidl W, Faison T, Crivelli JJ, Scherr DS, Bachmann A, Tewari AK, Kautzky-Willer A, Pummer K, Shariat SF. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate cancer and prostatic diseases 2013 Dec; 16(4).

Tewari N, Zaitoun AM, Lindsay D, Abbas A, Ilyas M, Lobo DN. Three cases of concomitant intraductal papillary mucinous neoplasm and pancreatic neuroendocrine tumour. JOP : Journal of the pancreas 2013 Jul; 14(4).

Sangwan A, Tewari S, Narula SC, Sharma RK, Sangwan P. Significance of periodontal health in primary immune thrombocytopenia- a case report and review of literature. Journal of dentistry (Tehran, Iran) 2013 Mar; 10(2).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Tewari did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

625 Madison Avenue
New York, NY 10022

Tel: 212-241-9955

Address

Icahn Medical Institute Floor 6th Floor Room L6-70
1425 Madison Avenue
New York, NY 10029

Tel: 212-241-2565
New Office

625 Madison Avenue
New York, NY 10022

Tel: 212-241-9955
Get Directions
Insurance Plans
  • Aetna HMO
  • Aetna PPO
  • Blue Cross/ Blue Shield
  • GHI CBP PPO
  • GHI HMO
  • HIP (all products EXCEPT Medicaid)
  • Medicare
  • Oxford Freedom
  • Railroad Medicare
  • United Health Care Empire Plan
  • United Healthcare